Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics, Inc. outlines a broad ophthalmology pipeline centered on gene therapies for inherited retinal diseases and a small-molecule eye drop franchise. The company’s lead gene therapy, OPGx-LCA5, has RMAT, Rare Pediatric Disease and Orphan designations and showed vision gains in six treated patients, supporting extension of the ongoing trial into an adaptive Phase 1/2/3 study with dosing planned after commercial-grade supply is ready in the second half of 2026.
OPGx-BEST1 is in a Phase 1/2 trial, where the first participant showed a 12-letter visual acuity gain and structural retinal improvement with good tolerability. Additional AAV programs target RHO, RDH12, MERTK, NMNAT1 and CNGB1, including a planned OPGx-MERTK trial in Abu Dhabi.
Beyond gene therapy, Opus’ phentolamine ophthalmic solution 0.75% is FDA‑approved as RYZUMVI for reversal of pharmacologically induced mydriasis and is partnered globally (excluding parts of Asia) with Viatris, which paid a $35 million upfront and a $10 million approval milestone. Multiple Phase 3 trials in presbyopia and dim‑light vision disturbances met primary endpoints, and the FDA has accepted a supplemental NDA for presbyopia with an October 17, 2026 PDUFA date. The company also describes Phase 2b data and a Special Protocol Assessment for oral small molecule APX3330 in diabetic retinopathy, while indicating it is seeking a partner to advance that program.
Opus Genetics reported full-year 2025 results alongside a broad pipeline update. License and collaboration revenue reached $14.2 million, up from $11.0 million in 2024, driven by R&D reimbursement from its Viatris collaboration. R&D expenses rose to $30.8 million and G&A expenses to $22.0 million, reflecting higher clinical, payroll, legal, and public company costs.
The company posted a net loss of $49.6 million, or ($0.80) per share, improving from a $57.5 million loss, mainly due to the absence of a $28.0 million acquired in‑process R&D charge recorded in 2024, partly offset by an $11.5 million increase in warrant and derivative liabilities. Cash and cash equivalents were $45.1 million at December 31, 2025, and a subsequent private placement raised about $25.0 million, giving aggregate cash resources of $70.1 million that are expected to fund operations into the first half of 2028.
Operationally, Opus highlighted favorable early safety and initial efficacy data from its OPGx‑BEST1 gene therapy, positive clinical results from its OPGx‑LCA5 program, and funding for its MERTK program. It also noted a Prescription Drug User Fee Act (PDUFA) decision date in October 2026 for Phentolamine Ophthalmic Solution 0.75% in presbyopia and emphasized that reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program could benefit its rare inherited retinal disease pipeline.
Opus Genetics, Inc. completed a $25.0 million private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock at $3.39 per share. These preferred shares are non-voting, rank on parity with common stock in a liquidation, and receive dividends as if converted to common.
Each preferred share will automatically convert into one share of common stock after stockholders approve an increase in authorized common shares at the 2026 annual meeting, subject to holder-set ownership caps between 0% and 19.9% of outstanding common stock. The company also granted investors registration rights to resell the common shares issuable upon conversion.
Opus Genetics plans to use the proceeds to advance its gene therapy clinical programs, working capital, and general corporate purposes. It reported preliminary cash of $45 million as of December 31, 2025, and a pro forma cash balance of $70 million after giving effect to the financing, with the year-end figures still unaudited and subject to adjustment.
Jayagopal Ashwath reported disposition transactions in a Form 4 filing for IRD. The filing lists transactions totaling 5,313 shares at a weighted average price of $3.39 per share. Following the reported transactions, holdings were 520,494 shares.
Perceptive Advisors and affiliates report passive beneficial ownership of 9.99% of Opus Genetics common stock. They collectively beneficially own 7,174,154 shares, combining common stock and warrant holdings calculated under Section 13(d) rules.
The Perceptive Life Sciences Master Fund directly holds 4,325,000 common shares, pre-funded warrants for 13,617,584 shares at an exercise price of $0.0001 per share, and common warrants for 13,157,895 shares at $0.95 per share. A 9.99% Beneficial Ownership Limitation in the warrants currently permits exercise for up to 2,849,154 shares, based on 68,964,208 shares outstanding as of November 10, 2025. Perceptive Advisors manages the Master Fund, and Joseph Edelman is its managing member.
Opus Genetics Inc. received a large shareholder disclosure from investment manager Balyasny Asset Management and related entities. They report beneficial ownership of 5,110,373 shares of common stock, equal to 7.41% of the company, based on 68,964,208 shares outstanding as of November 10, 2025.
The position includes 2,718,029 shares and 2,392,344 additional shares issuable upon exercise of warrants. Those warrants are subject to a blocker that prevents exercise if it would push ownership above 9.99% of outstanding shares. The holders state the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of Opus Genetics.
Nantahala Capital Management and its principals report a significant passive stake in Opus Genetics, Inc. As of December 31, 2025, they may be deemed to beneficially own 7,123,506 shares of common stock, representing 9.99% of the outstanding class.
This figure includes 2,342,176 shares that can be acquired within sixty days through warrant exercises. All voting and dispositive powers over the 7,123,506 shares are described as shared among Nantahala, Wilmot B. Harkey, and Daniel Mack, primarily through funds and separately managed accounts they oversee.
Blackwell Partners LLC - Series A, a fund advised by Nantahala, has the right to receive dividends or sale proceeds on more than five percent of the outstanding common stock. The reporting persons certify the holdings are in the ordinary course of business and not for changing or influencing control of Opus Genetics.
Opus Genetics, Inc. President and director Benjamin R. Yerxa reported an equity award in the form of 400,000 shares of common stock on January 22, 2026. The filing shows the shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 719,005 shares of common stock directly. According to the footnote, the award represents restricted stock units that vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, conditioned on his continued service.
Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, received a grant of 250,000 shares of common stock in the form of restricted stock units on 01/22/2026. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, conditioned on his continuing service with the company. The grant was recorded at a price of $0 per share, reflecting that no cash payment is required from him for the award. Following this transaction, he beneficially owns 304,500 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. granted 86,500 shares of its common stock in the form of restricted stock units to executive Amy Zaremba Rabourn, who serves as Head of Fin. Quality Assurance. The grant was made on January 22, 2026 at a price of $0 per share, reflecting an equity award rather than a market purchase.
The restricted stock units vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, as long as she continues in service. After this grant, she beneficially owns 193,128 shares of common stock directly.